Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma
By E. Wurmbach, Yingbei Chen, G. Khitrov, Weijia Zhang, S. Roayaie, M. Schwartz, I. Fiel, S. Thung, V. Mazzaferro, Jordi Bruix1 , 2 and 4 more. Hepatology, 2007
682 citations recorded by the source corpus.
Subfields: Hepatology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/25035b168f61eca6c9d65abea9b7703de71513cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Alejandro Forner1 , 2
- Andrew X. Zhu
- Peter R. Galle
- T. de Baère
In Oncology
In Pathology and Forensic Medicine
- Riccardo Lencioni
- J. Llovet
- Jordi Bruix1 , 2
- T. de Baère
- Andrew X. Zhu
- V. Mazzaferro
- Alejandro Forner1 , 2
- Peter W. Laird
Citations in the corpus
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “The performance of this signature was externally validated in a different set of samples [118,119].”
- Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. (2010, background): “PCGT mRNA expression also showed a gradual decrease with cancer progression in a data set including preneoplastic lesions (Supplemental Fig. 11; Wurmbach et al. 2007).”
- Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment (2010, background): “We first defined a human liver cirrhosis signature including 801 up-regulated and 445 down-regulated genes in comparison between 13 cirrhotic and 10 normal livers from publicly available dataset [13] (Table 1).”
- Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma (2007, background): “5 [1–1154] 5 [1–170] NS Nodule size (mm): <10 13 2 11 10–15 44 29 15 16–20 32 29 3 P 0.”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “The performance of this signature was externally validated in a different set of samples [118,119].”